Human cytomegalovirus neutralising antibodies and increased risk of coronary artery disease in Indian population

Background Several studies have reported a conflicting association between cytomegalovirus (CMV) infection and coronary artery disease (CAD) based on the levels of total anti-CMV antibodies. However, none have estimated the levels of specific neutralising antibodies (NA) to CMV, which may be clinically more relevant. Objective To determine whether CMV–NA titres show a better association with CAD compared with total anti-CMV antibody levels. Design CMV–NA titres were measured by micro-neutralisation assay and anti-CMV IgG antibodies using ELISA in 391 consecutive CAD patients compared with the same number of controls (N=782), and 91 patients reporting recurrent cardiac events during a 4-year follow-up compared with those without a recurrent event (N=182). Levels of inflammatory markers, interleukin 6, high-sensitivity C reactive protein, fibrinogen and secretory phospholipase A2 (sPLA2), were measured by ELISA. Analysis of variance and logistic regression were used for statistical analyses. Results High CMV–NA titres showed a positive association with CAD occurrence (OR 2.24, 95% CI 1.31 to 3.85, p=0.003) and recurrent cardiac events in CAD patients (OR 4.65, 95% CI 1.21 to 17.86, p=0.025) compared with total CMV antibodies (OR 1.67, 95% CI 1.04 to 2.69, p=0.034, and 2.70, 1.04 to 7.02, p=0.040, respectively). Patients with higher quartile of CMV–NA titres and sPLA2 levels had an adjusted OR of 7.82 (95% CI 1.87 to 32.65, 0.005) for recurrent cardiac events compared with those with the lowest quartiles for both markers. Conclusion These findings suggest that high CMV–NA titres in combination with inflammatory markers improve prediction of cardiac events in the Asian Indian population.

[1]  B. Nallamothu,et al.  Systems of care for ST-elevation myocardial infarction in India , 2011, Heart.

[2]  J. Pell,et al.  Prevention of cardiovascular disease in a rural region of India and strategies to address the unmet need , 2011, Heart.

[3]  V. Kakkar,et al.  Rationale, design & preliminary findings of the Indian Atherosclerosis Research Study. , 2010, Indian heart journal.

[4]  C. Sinzger,et al.  Endothelial cells in human cytomegalovirus infection: One host cell out of many or a crucial target for virus spread? , 2009, Thrombosis and Haemostasis.

[5]  M. Burnett,et al.  Insights Into the Role of Infection in Atherogenesis and in Plaque Rupture , 2009, Circulation.

[6]  Anders Larsson,et al.  Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. , 2008, The New England journal of medicine.

[7]  V. Singh,et al.  Reducing the burden of coronary artery disease in India: challenges and opportunities. , 2008, Indian heart journal.

[8]  B. Asselain,et al.  Circulating secretory phospholipase A2 activity predicts recurrent events in patients with severe acute coronary syndromes. , 2005, Journal of the American College of Cardiology.

[9]  A. Dogan,et al.  Are the high levels of cytomegalovirus antibodies a determinant in the development of coronary artery disease? , 2005, International heart journal.

[10]  M. Pfeffer,et al.  C-reactive protein levels and outcomes after statin therapy. , 2005, The New England journal of medicine.

[11]  S. Awasthi,et al.  Burden of infectious diseases in South Asia , 2004, BMJ : British Medical Journal.

[12]  D. Girelli,et al.  Interaction of antibodies against cytomegalovirus with heat-shock protein 60 in pathogenesis of atherosclerosis , 2003, The Lancet.

[13]  C. Visser,et al.  Type II secretory phospholipase A2 in cardiovascular disease: a mediator in atherosclerosis and ischemic damage to cardiomyocytes? , 2003, Cardiovascular research.

[14]  Fred Wang,et al.  Direct Relationship between Suppression of Virus-Specific Immunity and Emergence of Cytomegalovirus Disease in Simian AIDS , 2003, Journal of Virology.

[15]  M. Burnett,et al.  IL-6 is produced by splenocytes derived from CMV-infected mice in response to CMV antigens, and induces MCP-1 production by endothelial cells: a new mechanistic paradigm for infection-induced atherogenesis. , 2003, Atherosclerosis.

[16]  D. Levy,et al.  The association of seropositivity to Helicobacter pylori, Chlamydia pneumoniae, and cytomegalovirus with risk of cardiovascular disease: a prospective study. , 2002, Journal of the American College of Cardiology.

[17]  W. Jaross,et al.  Biological effects of secretory phospholipase A2 group IIA on lipoproteins and in atherogenesis , 2002, European journal of clinical investigation.

[18]  D. Bouley,et al.  Murine Cytomegalovirus CC Chemokine Homolog MCK-2 (m131-129) Is a Determinant of Dissemination That Increases Inflammation at Initial Sites of Infection , 2001, Journal of Virology.

[19]  M. Burnett,et al.  Cytomegalovirus infection increases development of atherosclerosis in Apolipoprotein-E knockout mice. , 2001, Atherosclerosis.

[20]  K. Radsak,et al.  Use of recombinant glycoprotein antigens gB and gH for diagnosis of primary human cytomegalovirus infection during pregnancy * , 2001, Journal of medical virology.

[21]  M. Eggers,et al.  Combination of microneutralization and avidity assays: Improved diagnosis of recent primary human cytomegalovirus infection in single serum sample of second trimester pregnancy , 2000, Journal of medical virology.

[22]  W. Jaross,et al.  Expression of secretory group IIA phospholipase A(2) in relation to the presence of microbial agents, macrophage infiltrates, and transcripts of proinflammatory cytokines in human aortic tissues. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[23]  A. Quyyumi,et al.  Cytomegalovirus in the pathogenesis of atherosclerosis: the role of inflammation as reflected by elevated C-reactive protein levels. , 1999, Journal of the American College of Cardiology.

[24]  T. Schall,et al.  Cytomegalovirus encodes a potent alpha chemokine. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[25]  J. Danesh,et al.  Chronic infection with Helicobacter pylori, Chlamydia pneumoniae, or cytomegalovirus: population based study of coronary heart disease , 1999, Heart.

[26]  W. Gibson,et al.  Identification of the human cytomegalovirus G protein-coupled receptor homologue encoded by UL33 in infected cells and enveloped virus particles. , 1996, Virology.

[27]  R. Ricciardi,et al.  An adenovirus recombinant that expresses the human cytomegalovirus major envelope glycoprotein and induces neutralizing antibodies. , 1990, The Journal of infectious diseases.

[28]  S. Plotkin,et al.  A rapid microneutralization assay for cytomegalovirus. , 1986, Journal of virological methods.

[29]  R. Levy,et al.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. , 1972, Clinical chemistry.

[30]  G. Vetrovec,et al.  Prior infection with cytomegalovirus is not a major risk factor for angiographically demonstrated coronary artery atherosclerosis. , 1998, The Journal of infectious diseases.